Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

RXRX

Recursion Pharmaceuticals Inc

Sep 13 • 04:00PM ET

6.57

Dollar change +0.07
Percentage change 1.08	%

Healthcare • Biotechnology • USA • NASD

Chart Stock Detail • Compare Perf. • Short Interest • Financials • Options • Save to Portfolio • Create Alert

Held by: ARKK ARKG VTI VB IWM XBI VXF VBK IWO IBB

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-1.62	Insider Own	22.59%	Shs Outstand	226.26M	Perf Week	10.98%
Market Cap	1.85B	Forward P/E	-	EPS next Y	-1.72	Insider Trans	-1.47%	Shs Float	218.47M	Perf Month	4.62%
Income	-374.93M	PEG	-	EPS next Q	-0.33	Inst Own	77.17%	Short Float	25.65%	Perf Quarter	-30.40%
Sales	49.63M	P/S	37.36	EPS this Y	1.11%	Inst Trans	3.80%	Short Ratio	9.87	Perf Half Y	-39.05%
Book/sh	2.08	P/B	3.16	EPS next Y	-10.01%	ROA	-51.98%	Short Interest	56.03M	Perf Year	-23.60%
Cash/sh	1.69	P/C	3.89	EPS next 5Y	12.00%	ROE	-71.18%	52W Range	4.97 - 15.74	Perf YTD	-33.37%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-43.41%	ROI	-57.01%	52W High	-58.26%	Beta	0.83
Dividend TTM	-	Quick Ratio	6.07	Sales past 5Y	132.77%	Gross Margin	-31.81%	52W Low	32.19%	ATR (14)	0.46
Dividend Ex-Date	-	Current Ratio	6.07	EPS Y/Y TTM	-17.59%	Oper. Margin	-817.09%	RSI (14)	45.79	Volatility	4.93% 6.13%
Employees	-	Debt/Eq	0.15	Sales Y/Y TTM	-0.70%	Profit Margin	-755.37%	Recom	2.50	Target Price	10.14
Option/Short	Yes / Yes	LT Debt/Eq	0.13	EPS Q/Q	-5.72%	Payout	-	Rel Volume	0.66	Prev Close	6.50
Sales Surprise	20.46%	EPS Surprise	-4.09%	Sales Q/Q	30.86%	Earnings	Aug 08 BMO	Avg Volume	5.67M	Price	6.57
SMA20	-4.60%	SMA50	-9.35%	SMA200	-27.46%	Trades		Volume	3,742,040	Change	1.08%

Date	Action	Analyst	Rating Change	Price Target Change
May-22-23	Initiated	Morgan Stanley	Equal-Weight	$8
Mar-16-23	Initiated	Needham	Buy	$17
Sep-16-22	Initiated	KeyBanc Capital Markets	Overweight	$20
Apr-18-22	Downgrade	BofA Securities	Buy → Neutral	$10
Mar-04-22	Downgrade	SVB Leerink	Outperform → Mkt Perform	$10
Sep-21-21	Initiated	Berenberg	Buy	$37
May-11-21	Initiated	SVB Leerink	Outperform	$33
May-11-21	Initiated	KeyBanc Capital Markets	Overweight	$36
May-11-21	Initiated	JP Morgan	Neutral	$32
May-11-21	Initiated	Goldman	Neutral	$34
May-11-21	Initiated	BofA Securities	Buy	$31

Show Previous Ratings

Sep-12-24 10:53AM	Recursion Pharmaceuticals, Inc. (RXRX): A Very Important AI Stock According to BlackRock (Insider Monkey)
Sep-08-24 04:51PM	Recursion Pharmaceuticals, Inc. (RXRX): Among the Worst ARK Stocks According to Short Sellers (Insider Monkey)
11:49AM	10 Worst ARK Stocks To Buy According To Short Sellers (Insider Monkey)
Sep-03-24 08:00AM	Recursion Announces Phase 2 Data of REC-994, a First-in-Disease Investigational Treatment for Symptomatic Cerebral Cavernous Malformation (CCM), has Met its Primary Endpoint of Safety and Tolerability (GlobeNewswire) -16.62%
07:11AM	AI specialist Recursion says lead drug is safe, but efficacy less clear (BioPharma Dive)
04:10AM	Loading…
Aug-30-24 04:10AM	Is Recursion Pharmaceuticals a Warren Buffett Stock? (Motley Fool)
Aug-28-24 07:04PM	Recursion Pharmaceuticals Inc. (RXRX): Among The Best Medical AI Companies (Insider Monkey)
Aug-18-24 12:34PM	The Bull Thesis for Recursion Pharmaceuticals Stock Just Got Stronger. Here's Why. (Motley Fool)
Aug-17-24 09:53AM	Is Recursion Pharmaceuticals Stock a Buy? (Motley Fool)
Aug-16-24 06:36PM	These Stocks in Nvidia's Portfolio Took a Hit in the Second Quarter (Investopedia) +6.08%
Aug-14-24 09:45AM	How A.I. Is Shaping the Future of U.S. Healthcare: Regulatory and Market Updates (GlobeNewswire)
Aug-13-24 07:05AM	Prediction: Artificial Intelligence Will Lead to Higher Returns With Biotech Stocks (Motley Fool) +8.46%
Aug-12-24 09:15AM	Prediction: Buying Biotech and Pharma Stocks During This Sell-Off Will Be a Smart Move (Motley Fool)
Aug-11-24 04:59AM	Is Recursion Pharmaceuticals a Buy Ahead of Its Merger With Exscientia? (Motley Fool)
Aug-08-24 05:37PM	AI-Powered Drug Discovery Firm Exscientia To Merge With Nvidia-Partner Recursion Pharmaceuticals (Benzinga) -5.27%
02:41PM	Loading…
02:41PM	CORRECTION - Recursion Provides Business Updates and Reports Second Quarter 2024 Financial Results (GlobeNewswire)
08:45AM	Recursion Pharmaceuticals (RXRX) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
07:45AM	Recursion Pharmaceuticals: Q2 Earnings Snapshot (Associated Press Finance)
07:39AM	Recursion and Exscientia Enter Definitive Agreement to Create a Global Technology-Enabled Drug Discovery Leader with End-to-End Capabilities (GlobeNewswire)
07:30AM	Recursion Provides Business Updates and Reports Second Quarter 2024 Financial Results (GlobeNewswire)
07:07AM	Biotech firm Recursion to buy smaller peer Exscientia for $688 million (Reuters)
01:32AM	Recursion updates L(earnings) call on August 8th to 8:30 am ET / 6:30 am MT (GlobeNewswire)
Aug-06-24 06:00AM	Is Recursion Pharmaceuticals a Millionaire-Maker? (Motley Fool)
Aug-05-24 04:01PM	Recursion to Report Second Quarter 2024 Business Updates and Financial Results on August 8th (GlobeNewswire)
Jul-31-24 05:06AM	99.9% of Nvidia's $380 Million Investment Portfolio Has Been Put to Work in These 4 Artificial Intelligence (AI)-Inspired Stocks (Motley Fool)
Jul-29-24 05:50PM	Recursion Pharmaceuticals (RXRX) Stock Sinks As Market Gains: Here's Why (Zacks)
Jul-27-24 05:41AM	Down About 47% This Year: Is Recursion Pharmaceuticals a Buy on the Dip? (Motley Fool)
Jul-26-24 09:55AM	Wall Street Analysts Predict a 43.73% Upside in Recursion Pharmaceuticals (RXRX): Here's What You Should Know (Zacks)
Jul-18-24 06:10AM	3 Millionaire-Maker Artificial Intelligence (AI) Stocks (Motley Fool) -5.75%
Jul-14-24 06:25AM	Is Recursion Pharmaceuticals Stock a Buy? (Motley Fool)
09:29AM	Loading…
Jul-13-24 09:29AM	1 Reason to Buy Recursion Pharmaceuticals Stock and 2 Reasons to Sell (Motley Fool)
06:26AM	3 Healthcare Stocks Injecting AI for Big Gains (InvestorPlace)
Jul-12-24 05:50AM	These Nvidia-Backed Artificial Intelligence (AI) Stocks Could Soar 73% to 89% Higher, According to Wall Street (Motley Fool) +8.85%
Jul-08-24 07:09PM	3 Longevity Stocks to Buy for Anti-Aging Breakthroughs (InvestorPlace)
Jul-03-24 09:12AM	3 Stocks This Amazon-Backed AI Says Will Turn $1K into $1M by 2030 (InvestorPlace)
Jun-28-24 10:28AM	Treasure Hunt: 3 Biotech Stocks Wall Street Hasn't Discovered Yet (InvestorPlace)
03:48AM	Insider Sale: Director Blake Borgeson Sells Shares of Recursion Pharmaceuticals Inc (RXRX) (GuruFocus.com)
Jun-27-24 08:15AM	3 AI Stocks on the Edge of a Massive Surge (InvestorPlace) -13.53%
07:34AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday (InvestorPlace)
Jun-26-24 10:07PM	Recursion Announces Pricing of $200 Million Public Offering of Class A Common Stock (GlobeNewswire) -6.61%
04:06PM	Recursion Announces Proposed Offering of Class A Common Stock (GlobeNewswire)
Jun-25-24 05:50PM	Recursion Pharmaceuticals (RXRX) Surpasses Market Returns: Some Facts Worth Knowing (Zacks)
Jun-24-24 09:00AM	Helix and Recursion Pharmaceuticals Drive Drug Discovery Innovation Through Clinico-Genomic Data (Business Wire) +5.54%
08:00AM	Recursion Gives Guidance on Seven Clinical Readouts within ~18 Months and Partnership Updates at Their Download Day (GlobeNewswire)
Jun-13-24 02:40PM	3 Stocks Under $10 Set to Quadruple by 2025: June Edition (InvestorPlace)
Jun-08-24 11:37AM	Nvidia Owns These 4 Stocks. Heres How Theyre Doing. (Barrons.com)
Jun-07-24 09:00AM	Recursion Pharmaceuticals Stock Could Be a 10-Bagger, but Only if It Comes Through on This Big Claim (Motley Fool) -5.55%
Jun-05-24 06:26AM	Nvidia's Golden Handshake: 3 Stocks Reaping the Rewards of an NVDA Alliance (InvestorPlace) +8.09%
Jun-03-24 09:00AM	Recursion to Participate in Upcoming Investor Conferences (GlobeNewswire)
06:15AM	Cathie Wood Owns These 2 AI Stocks. Should You? (Motley Fool)
Jun-02-24 03:40AM	Is Recursion Pharmaceuticals Stock a Millionaire-Maker? (Motley Fool)
May-31-24 02:46AM	Insider Sale: Director Blake Borgeson Sells Shares of Recursion Pharmaceuticals Inc (RXRX) (GuruFocus.com) -6.65%
May-30-24 04:46AM	Hedge Funds are Loading Up on This NVIDIA Corp (NVDA) Partner Stock (Insider Monkey)
04:32AM	7 Best Under-The-Radar AI Stocks Hedge Funds are Buying (Insider Monkey)
May-29-24 03:27PM	Power of Recursion OS on Display at Genome Scale in Nature Genetics Paper Detailing Potential Limitation of CRISPR Gene Editing Tool (GlobeNewswire)
May-24-24 04:30PM	Recursion Appoints Robert Hershberg M.D., Ph.D, as New Chair of the Board (GlobeNewswire)
06:30AM	2 Stocks That Could 10x by 2035 (Motley Fool)
May-23-24 09:00AM	Here is What to Know Beyond Why Recursion Pharmaceuticals, Inc. (RXRX) is a Trending Stock (Zacks)
May-17-24 02:36AM	Director Blake Borgeson Sells 20,054 Shares of Recursion Pharmaceuticals Inc (RXRX) (GuruFocus.com)
May-15-24 08:45AM	What's the Difference Between Biotech Stocks and TechBio Stocks? (Motley Fool)
May-13-24 09:59AM	Recursion Pharmaceuticals Says BioHive-2 AI Supercomputer Completed (MT Newswires) +10.23%
05:00AM	Recursion Announces Completion of NVIDIA-Powered BioHive-2, the Largest Supercomputer in Pharmaceutical Industry (GlobeNewswire)
May-12-24 08:15AM	Cathie Wood Is Buying This Under-the-Radar AI Stock (Motley Fool)
May-10-24 08:05PM	Recursion Pharmaceuticals CEO Chris Gibson goes one-on-one with Jim Cramer (CNBC TV) +10.23%
01:26PM	Recursion Pharmaceuticals Inc (RXRX) Q1 2024 Earnings: Revenue Surpasses Estimates Amid ... (GuruFocus.com)
12:36PM	Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Q1 2024 Earnings Call Transcript (Insider Monkey)
May-09-24 08:59PM	RXRX Stock Earnings: Recursion Pharmaceuticals Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace)
06:04PM	Recursion Pharmaceuticals Q1 Loss Widens, Revenue Rises (MT Newswires)
05:25PM	Recursion Pharmaceuticals (RXRX) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
04:32PM	Recursion Pharmaceuticals: Q1 Earnings Snapshot (Associated Press Finance)
04:01PM	Recursion Provides Business Updates and Reports First Quarter 2024 Financial Results (GlobeNewswire)
May-06-24 11:41AM	Recursion (RXRX) to Report Q1 Earnings: What's in the Cards? (Zacks)
May-03-24 05:50PM	Recursion Pharmaceuticals (RXRX) Increases Yet Falls Behind Market: What Investors Need to Know (Zacks)
May-02-24 09:00AM	Recursion Pharmaceuticals, Inc. (RXRX) is Attracting Investor Attention: Here is What You Should Know (Zacks) +5.40%
08:00AM	Recursion to Report First Quarter 2024 Business Updates and Financial Results on May 9 (GlobeNewswire)
May-01-24 08:01AM	Recursion to Participate in Upcoming Investor Conferences (GlobeNewswire) +6.65%
Apr-30-24 08:00AM	Altitude Lab Secures Small Business Administration Growth Fund Accelerator Grant to Launch Horizon, a Commercialization Partnering Program (GlobeNewswire)
07:29AM	Jim Cramer is Recommending These 10 Stocks Heading Into May 2024 (Insider Monkey)
Apr-27-24 08:58AM	Nvidia Owns a 3.4% Stake in This Innovative Artificial Intelligence (AI) Stock Cathie Wood Loves (Motley Fool)
07:00AM	The Top 3 Biotech Stocks to Buy in April 2024 (InvestorPlace)
Apr-25-24 05:50PM	Recursion Pharmaceuticals (RXRX) Declines More Than Market: Some Information for Investors (Zacks)
10:30AM	3 Millionaire-Maker Biotech Stocks (Motley Fool)
08:01AM	AI in Healthcare: Unveiling the Future with a 42.20% CAGR Through 2029 (PR Newswire)
Apr-17-24 05:50PM	Recursion Pharmaceuticals (RXRX) Dips More Than Broader Market: What You Should Know (Zacks)
07:00AM	Where Will Recursion Pharmaceuticals Be in 5 Years? (Motley Fool)
Apr-16-24 08:00AM	Recursion Appoints Najat Khan, PhD, as Chief R&D Officer and Chief Commercial Officer (GlobeNewswire)
Apr-15-24 12:54PM	Biotech on a Budget: 7 Stocks Under $10 With Huge Potential (InvestorPlace) -7.37%
08:00AM	Wall Street Favorites: 3 Cathie Wood Stocks With Strong Buy Ratings for April 2024 (InvestorPlace)
Apr-10-24 05:50AM	Can Recursion Pharmaceuticals Stock Double in 5 Years? Here's What It Would Take. (Motley Fool) -5.61%
Apr-08-24 09:00AM	The AI Advantage: 2 Healthcare Stocks at the Forefront of Innovation (Motley Fool)
Apr-04-24 08:45AM	Is This Under-the-Radar Artificial Intelligence (AI) Stock a Buy? (Motley Fool)
01:31AM	Recursion Pharmaceuticals Inc Director Blake Borgeson Sells 11,447 Shares (GuruFocus.com)
Apr-03-24 09:35AM	Down -26.36% in 4 Weeks, Here's Why Recursion Pharmaceuticals (RXRX) Looks Ripe for a Turnaround (Zacks)
Apr-02-24 08:00AM	Recursion to Participate in Upcoming Investor Conference (GlobeNewswire) -6.40%
Apr-01-24 12:00PM	All You Need to Know About Recursion Pharmaceuticals (RXRX) Rating Upgrade to Buy (Zacks) -6.02%
Mar-26-24 08:00AM	Recursion Publishes Annual Environmental, Social and Governance Report (GlobeNewswire)
Mar-22-24 01:29AM	Recursion Pharmaceuticals Inc Director Blake Borgeson Sells 20,054 Shares (GuruFocus.com)
Mar-18-24 01:00PM	New COVID-Like Outbreak 'Matter Of When, Not If,' WHO Director Warns As Scientists Race To Prepare Using Artificial Intelligence (Benzinga)
Mar-15-24 04:54PM	Since Nvidia Disclosed Stakes in These Stocks, They've Soared (Investopedia)
01:49AM	Recursion Pharmaceuticals Inc CFO Michael Secora Sells 50,000 Shares (GuruFocus.com)

Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, and in vivo validation capabilities to discover novel medicines. Its Recursion operating system enables advanced machine learning approaches to reveal drug candidates, mechanisms of action, novel chemistry, and potential toxicity, with the eventual goal of decoding biology and advancing new therapeutics that radically improve people's lives. The company was founded by Blake Borgeson, Christopher C. Gibson, and Dean Y. Li on November 5, 2013 and is headquartered in Salt Lake City, UT.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Secora Michael	Chief Financial Officer	Sep 10 '24	Option Exercise	2.22	39,375	87,413	1,392,756	Sep 12 06:28 PM
Secora Michael	Chief Financial Officer	Sep 11 '24	Option Exercise	2.22	39,375	87,413	1,417,131	Sep 12 06:28 PM
Secora Michael	Chief Financial Officer	Sep 11 '24	Sale	6.32	15,000	94,730	1,402,131	Sep 12 06:28 PM
Secora Michael	Chief Financial Officer	Sep 10 '24	Sale	6.17	15,000	92,499	1,377,756	Sep 12 06:28 PM
Secora Michael	Officer	Sep 11 '24	Proposed Sale	6.32	15,000	94,730		Sep 11 05:15 PM
Secora Michael	Officer	Sep 10 '24	Proposed Sale	6.17	15,000	92,499		Sep 10 05:00 PM
Gibson Christopher	Chief Executive Officer	Sep 05 '24	Sale	6.14	20,000	122,800	762,656	Sep 06 04:57 PM
Gibson Christopher	Chief Executive Officer	Sep 04 '24	Sale	6.04	20,000	120,800	762,656	Sep 06 04:57 PM
Borgeson Blake	Director	Sep 03 '24	Sale	6.27	11,447	71,718	7,121,322	Sep 05 05:25 PM
Gibson Christopher	Officer	Sep 05 '24	Proposed Sale	6.14	20,000	122,800		Sep 05 11:43 AM
Gibson Christopher	Officer	Sep 04 '24	Proposed Sale	6.04	20,000	120,800		Sep 04 01:16 PM
Marriott Tina	President and COO	Aug 29 '24	Option Exercise	1.06	6,000	6,360	527,138	Sep 03 04:48 PM
Marriott Tina	President and COO	Aug 29 '24	Sale	7.56	6,000	45,376	521,138	Sep 03 04:48 PM
Borgeson Blake	Director	Sep 03 '24	Proposed Sale	6.27	11,447	71,717		Sep 03 04:27 PM
Gibson Christopher	Chief Executive Officer	Aug 30 '24	Option Exercise	2.48	5,000	12,400	762,656	Aug 30 04:26 PM
Marriott Tina	Officer	Aug 29 '24	Proposed Sale	7.56	6,000	45,376		Aug 29 04:53 PM
Gibson Christopher	Chief Executive Officer	Aug 29 '24	Option Exercise	2.48	5,000	12,400	757,656	Aug 29 04:22 PM
Gibson Christopher	Chief Executive Officer	Aug 28 '24	Option Exercise	2.48	5,000	12,400	752,656	Aug 28 04:12 PM
Gibson Christopher	Chief Executive Officer	Aug 27 '24	Option Exercise	2.48	5,000	12,400	747,656	Aug 27 04:10 PM
Gibson Christopher	Chief Executive Officer	Aug 26 '24	Option Exercise	2.48	5,000	12,400	742,656	Aug 26 04:42 PM
Gibson Christopher	Chief Executive Officer	Aug 23 '24	Option Exercise	2.48	5,000	12,400	737,656	Aug 23 05:25 PM
Borgeson Blake	Director	Aug 20 '24	Sale	7.12	11,447	81,532	7,132,769	Aug 22 06:48 PM
Borgeson Blake	Director	Aug 20 '24	Proposed Sale	7.12	11,447	81,533		Aug 20 04:25 PM
Secora Michael	Chief Financial Officer	Aug 13 '24	Option Exercise	2.22	39,375	87,413	1,355,968	Aug 15 05:24 PM
Secora Michael	Chief Financial Officer	Aug 14 '24	Option Exercise	2.22	39,375	87,413	1,380,343	Aug 15 05:24 PM
Secora Michael	Chief Financial Officer	Aug 14 '24	Sale	6.35	15,000	95,252	1,365,343	Aug 15 05:24 PM
Secora Michael	Chief Financial Officer	Aug 13 '24	Sale	6.35	15,000	95,182	1,340,968	Aug 15 05:24 PM
Secora Michael	Officer	Aug 14 '24	Proposed Sale	6.35	15,000	95,251		Aug 14 04:35 PM
Secora Michael	Officer	Aug 13 '24	Proposed Sale	6.35	15,000	95,183		Aug 13 04:22 PM
Gibson Christopher	Chief Executive Officer	Aug 07 '24	Sale	7.10	30,000	213,000	758,738	Aug 09 04:56 PM
Gibson Christopher	Chief Executive Officer	Aug 08 '24	Sale	6.50	20,000	130,000	758,738	Aug 09 04:56 PM
Borgeson Blake	Director	Aug 06 '24	Sale	6.82	11,447	78,083	7,144,216	Aug 08 05:23 PM
Gibson Christopher	Officer	Aug 08 '24	Proposed Sale	6.50	20,000	130,000		Aug 08 12:56 PM
Gibson Christopher	Officer	Aug 07 '24	Proposed Sale	7.10	30,000	213,000		Aug 07 01:34 PM
Borgeson Blake	Director	Aug 06 '24	Proposed Sale	6.82	11,447	78,083		Aug 06 04:50 PM
Marriott Tina	President and COO	Jul 25 '24	Option Exercise	1.06	6,000	6,360	541,457	Jul 29 06:16 PM
Marriott Tina	President and COO	Jul 25 '24	Sale	8.13	6,000	48,809	535,457	Jul 29 06:16 PM
Borgeson Blake	Director	Jul 23 '24	Sale	8.48	11,447	97,041	7,155,663	Jul 25 06:15 PM
Gibson Christopher	Chief Executive Officer	Jul 10 '24	Sale	7.48	50,000	374,000	758,738	Jul 12 06:54 PM
Gibson Christopher	Chief Executive Officer	Jul 11 '24	Sale	7.47	50,000	373,500	758,738	Jul 12 06:54 PM
Secora Michael	Chief Financial Officer	Jul 09 '24	Option Exercise	2.22	39,375	87,413	1,307,218	Jul 11 04:51 PM
Secora Michael	Chief Financial Officer	Jul 10 '24	Option Exercise	2.22	39,375	87,413	1,331,593	Jul 11 04:51 PM
Secora Michael	Chief Financial Officer	Jul 09 '24	Sale	7.32	15,000	109,778	1,292,218	Jul 11 04:51 PM
Secora Michael	Chief Financial Officer	Jul 10 '24	Sale	7.24	15,000	108,576	1,316,593	Jul 11 04:51 PM
Borgeson Blake	Director	Jul 09 '24	Sale	7.32	11,447	83,735	7,167,110	Jul 11 04:51 PM
Marriott Tina	President and COO	Jun 27 '24	Option Exercise	1.06	6,000	6,360	541,457	Jun 28 05:14 PM
Marriott Tina	President and COO	Jun 27 '24	Sale	7.21	6,000	43,290	535,457	Jun 28 05:14 PM
Borgeson Blake	Director	Jun 25 '24	Sale	9.51	11,447	108,806	7,177,116	Jun 27 07:13 PM
Secora Michael	Chief Financial Officer	Jun 13 '24	Option Exercise	2.22	39,375	87,413	1,258,468	Jun 17 05:46 PM
Secora Michael	Chief Financial Officer	Jun 14 '24	Option Exercise	2.22	39,375	87,413	1,282,843	Jun 17 05:46 PM
Secora Michael	Chief Financial Officer	Jun 13 '24	Sale	9.32	15,000	139,798	1,243,468	Jun 17 05:46 PM
Secora Michael	Chief Financial Officer	Jun 14 '24	Sale	9.27	15,000	139,082	1,267,843	Jun 17 05:46 PM
Borgeson Blake	Director	Jun 11 '24	Sale	8.45	11,447	96,763	7,188,563	Jun 13 05:36 PM
Gibson Christopher	Chief Executive Officer	Jun 06 '24	Sale	9.00	50,000	450,000	708,738	Jun 07 04:01 PM
Gibson Christopher	Chief Executive Officer	Jun 05 '24	Sale	8.42	50,000	421,000	758,738	Jun 07 04:01 PM
Marriott Tina	President and COO	May 30 '24	Option Exercise	1.06	3,000	3,180	538,457	Jun 03 06:31 PM
Marriott Tina	President and COO	May 30 '24	Sale	8.78	3,000	26,325	535,457	Jun 03 06:31 PM
Borgeson Blake	Director	May 28 '24	Sale	9.17	11,447	104,943	7,186,913	May 30 06:41 PM
Borgeson Blake	Director	May 14 '24	Sale	10.12	20,054	202,934	7,198,360	May 16 04:35 PM
Gibson Christopher	Chief Executive Officer	May 02 '24	Sale	8.47	50,000	423,500	834,820	May 03 06:24 PM
Gibson Christopher	Chief Executive Officer	May 01 '24	Sale	7.73	50,000	386,500	863,524	May 03 06:24 PM
Borgeson Blake	Director	Apr 30 '24	Sale	7.95	11,447	90,964	7,218,414	May 02 05:41 PM
Marriott Tina	President and COO	Apr 25 '24	Option Exercise	1.06	3,000	3,180	546,231	Apr 29 06:41 PM
Marriott Tina	President and COO	Apr 25 '24	Sale	7.67	3,000	23,020	543,231	Apr 29 06:41 PM
Borgeson Blake	Director	Apr 16 '24	Sale	7.66	11,447	87,725	7,229,861	Apr 18 05:12 PM
Secora Michael	Chief Financial Officer	Apr 16 '24	Option Exercise	2.22	37,500	83,250	1,241,679	Apr 18 05:12 PM
Secora Michael	Chief Financial Officer	Apr 17 '24	Option Exercise	2.22	37,500	83,250	1,254,179	Apr 18 05:12 PM
Secora Michael	Chief Financial Officer	Apr 16 '24	Sale	7.67	25,000	191,658	1,216,679	Apr 18 05:12 PM
Secora Michael	Chief Financial Officer	Apr 17 '24	Sale	7.58	23,124	175,349	1,231,055	Apr 18 05:12 PM
Gibson Christopher	Chief Executive Officer	Apr 04 '24	Sale	9.02	40,000	360,800	938,524	Apr 05 05:44 PM
Gibson Christopher	Chief Executive Officer	Apr 03 '24	Sale	8.84	40,000	353,600	978,524	Apr 05 05:44 PM
Gibson Christopher	Chief Executive Officer	Apr 04 '24	Sale	9.02	25,000	225,500	0	Apr 05 05:44 PM
Gibson Christopher	Chief Executive Officer	Apr 03 '24	Sale	8.84	25,000	221,000	0	Apr 05 05:44 PM
Borgeson Blake	Director	Apr 02 '24	Sale	8.82	11,447	100,942	7,241,308	Apr 03 05:42 PM
Gibson Christopher	Chief Executive Officer	Mar 28 '24	Sale	10.10	40,000	404,000	1,043,524	Apr 01 06:40 PM
Gibson Christopher	Chief Executive Officer	Mar 28 '24	Sale	10.10	25,000	252,500	0	Apr 01 06:40 PM
Marriott Tina	President and COO	Mar 21 '24	Option Exercise	1.06	8,000	8,480	647,982	Mar 25 06:39 PM
Marriott Tina	President and COO	Mar 21 '24	Sale	10.75	8,000	85,980	639,982	Mar 25 06:39 PM
Borgeson Blake	Director	Mar 19 '24	Sale	10.79	20,054	216,423	7,252,755	Mar 21 05:38 PM
Secora Michael	Chief Financial Officer	Mar 12 '24	Option Exercise	2.22	37,500	83,250	1,216,679	Mar 14 07:28 PM
Secora Michael	Chief Financial Officer	Mar 13 '24	Option Exercise	2.22	37,500	83,250	1,229,179	Mar 14 07:28 PM
Secora Michael	Chief Financial Officer	Mar 13 '24	Sale	11.03	25,000	275,815	1,204,179	Mar 14 07:28 PM
Secora Michael	Chief Financial Officer	Mar 12 '24	Sale	10.46	25,000	261,375	1,191,679	Mar 14 07:28 PM
Gibson Christopher	Chief Executive Officer	Mar 06 '24	Option Exercise	4.42	39,924	176,384	1,144,843	Mar 08 07:08 PM
Gibson Christopher	Chief Executive Officer	Mar 06 '24	Sale	11.86	36,319	430,682	1,108,524	Mar 08 07:08 PM
Gibson Christopher	Chief Executive Officer	Mar 06 '24	Sale	11.55	25,000	288,823	0	Mar 08 07:08 PM
Borgeson Blake	Director	Mar 05 '24	Sale	12.06	20,054	241,805	7,272,809	Mar 07 06:53 PM
Marriott Tina	President and COO	Feb 22 '24	Option Exercise	1.06	8,000	8,480	647,982	Feb 23 07:22 PM
Marriott Tina	President and COO	Feb 22 '24	Sale	14.89	8,000	119,160	639,982	Feb 23 07:22 PM
Borgeson Blake	Director	Feb 20 '24	Sale	12.32	20,054	247,125	7,292,863	Feb 21 05:37 PM
Secora Michael	Chief Financial Officer	Feb 13 '24	Option Exercise	2.22	37,500	83,250	1,198,851	Feb 15 06:00 PM
Secora Michael	Chief Financial Officer	Feb 14 '24	Option Exercise	2.22	37,500	83,250	1,211,351	Feb 15 06:00 PM
Secora Michael	Chief Financial Officer	Feb 14 '24	Sale	10.46	25,000	261,425	1,186,351	Feb 15 06:00 PM
Secora Michael	Chief Financial Officer	Feb 13 '24	Sale	9.86	25,000	246,560	1,173,851	Feb 15 06:00 PM
Gibson Christopher	Chief Executive Officer	Feb 07 '24	Option Exercise	2.48	31,250	77,500	822,975	Feb 09 05:34 PM
Gibson Christopher	Chief Executive Officer	Feb 07 '24	Sale	9.22	48,272	444,981	774,703	Feb 09 05:34 PM
Borgeson Blake	Director	Feb 06 '24	Sale	9.30	11,447	106,489	7,312,917	Feb 08 06:54 PM
Larson Tina Marriott	President and COO	Jan 25 '24	Option Exercise	1.06	8,000	8,480	422,584	Jan 29 06:52 PM
Larson Tina Marriott	President and COO	Jan 25 '24	Sale	10.35	8,000	82,762	414,548	Jan 29 06:52 PM
Borgeson Blake	Director	Jan 23 '24	Sale	10.58	20,054	212,083	7,324,364	Jan 25 06:13 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

RXRX

Recursion Pharmaceuticals Inc

Upgrade your FINVIZ experience